Faculty

Institution

Unit

Venue

Chetan Vakkalagadda, M.D.

Assistant Professor of Medicine Division of Hematology/Medical Oncology

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Otolaryngology - Head And Neck Surgery

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Center Of Molecular Biology Of Head And Neck Cancer

Molecular Biology of Head and Neck Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Chetan Vakkalagadda, M.d. is currently serving as a Biostatistics Shared Resources Assistant Professor of Medicine Division of Hematology/Medical Oncology at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Chetan Vakkalagadda, M.D.

Oregon Health & Science University

Assistant Professor of Medicine Division of Hematology/Medical Oncology

You can click a keyword to filter the displayed items

oncology medicine clinical research pharmacology radiation oncology hematology cancer care immunology thoracic oncology cancer treatment cancer genetics nephrology medicinal research molecular cancer thoracic surgery oncogenes transplantation medicine post-transplant lymphoproliferative disorder cancer immunotherapy therapeutic targets outcomes research metastasis leukemia jama oncology laboratory medicine enzyme inhibition surgical oncology medical mycology autophagy molecular diagnostics disease progression prognosis treatment and prevention oral cancer therapeutic efficacy colorectal cancer drug targeting cancer biology genomic medicine cancer genomics next-generation sequencing clinical translation pathologic response rectal cancer metformin use phase ii study autophagy modulation standard therapy surgical resection extranodal disease involvement northwestern university immunosuppressive agents posttransplant lymphoproliferative disorder advanced nsclc recurrent high-grade crs retrospective analysis next-generation sequencing workflows pathology translational research survival analysis sarcoma cancer cells gynecologic cancers gynecologic oncology lung cancer medical sociology histopathology cancer research cancer letter neuro-oncology alternative medicine tumor biology dermatology carcinogenesis medical history breast cancer brain tumor research cervical cancer mesothelioma cancer imaging oral pathology surgical pathology thyroid internal medicine tumor microenvironment anatomical pathology integrative medicine cancer discovery translational medicine mortality nuclear medicine

Notable Scholarly Works

Notable Federal Grants

Collaborators

Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated Sclc: A Case Report. JTO Clinical and Research Reports (2026)

recurrent high-grade crsmedicinepharmacologyhematologyclinical researchpathologytranslational medicine

Impact of Incidental Germline Brca1/2 and Palb2 Alterations on Egfr Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer (2025)

Utilizing Tp53 Mutation Status and Initial Disease Burden at Presentation to Risk-Stratify Patients With Advanced Egfr-Mutated Nsclc Treated With Osimertinib.. Journal of Clinical Oncology (2025)

medicineadvanced egfr-mutated nsclccancer geneticsradiation oncologycancer researchmolecular cancermolecular diagnosticsoncologyinitial disease burdenoncogenescancer treatmenttp53 mutation statuspathologyclinical translationmolecular medicine

Pp01.124 Impact of Comprehensive vs Limited Ngs on Time to Result and Time to Treatment in Advanced Nsclc. Journal of Thoracic Oncology (2024)

Danielle DresslerChetan V. VakkalagaddaZequn SunJoseph R. FuchsAlex LiuPhilip SilbermanMasha KocherginskyYanis BoumberYoung ChaeAvanthi RagamJyoti PatelNisha Mohindra

surgerymedicinecancer carethoracic oncologyradiation oncologyadvanced nsclcthoracic surgeryoncologybreast cancerclinical researchlung cancer

The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System. Cancers (2024)

Chetan V. VakkalagaddaDanielle B. DresslerZequn SunJoseph FuchsYingzhe LiuPhilip SilbermanAvanthi RagamSheetal KircherJyoti D. PatelNisha A. Mohindra

retrospective analysisnext-generation sequencing workflowsnext-generation sequencingadvanced lung canceracademic health systemlung cancerhealth sciences

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With Ret Fusion-Driven Nsclc and an Acquired Her2 Amplification: Case Report. JTO Clinical and Research Reports (2023)

A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Addition to Encorafenib and Cetuximab or Panitumumab in Metastatic Braf-Mutated Colorectal Cancer Refractory to Standard Therapy.. Journal of Clinical Oncology (2023)

Chetan VakkalagaddaSabeeha MukitMasha KocherginskySheetal Mehta KircherAparna KalyanMary Frances MulcahyAl Bowen BensonNavdeep ChandelDevalingam Mahalingam

cancer geneticsphase ii studyautophagymedicinecancer carecolorectal cancercancer biologyhealth sciencesstandard therapycancer researchhepatologydrug targetingcancer treatmentautophagy modulationmedical mycologypharmacologythoracic oncologypersonalized medicineoncologyclinical researchmedicinal research

Ep07.04-10 Early-Stage Egfr Mutated Nsclc: Outcomes After Surgical Resection at a Large Academic Medical Center. Journal of Thoracic Oncology (2023)

C. VakkalagaddaD. DresslerJ. FuchsN. KatamM. GurleyN. MohindraY.K. ChaeL. FerrisA. WanA. RagamS. KimA. BharatD. OdellJ. Patel

medicinecancer geneticscancer caregenomic medicinethoracic oncologyradiation oncologycancer researchmolecular cancergeneticsthoracic surgerycancer genomicssurgical resectiononcologybreast canceroncogeneslung cancertumor biology

Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder. Blood (2022)

Megan MelodyFrederique St. PierreIrene HelenowskiWilliam B PearseChetan V VakkalagaddaJoseph R. LeventhalJohn FriedewaldBing HoDaniel GangerJane N. WinterLeo I. GordonAdam Yuh LinReem KarmaliShuo MaBarbara ProJonathan Moreira

immunologydermatologymedicinehematologynephrologyextranodal disease involvementtransplantation medicineoncologypost-transplant lymphoproliferative disorder

Posttransplant Lymphoproliferative Disorder (Ptld) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in Ptld. Blood (2022)

Megan MelodyFrederique St. PierreIrene HelenowskiWilliam B PearseChetan VakkalagaddaJoseph R. LeventhalBing HoJohn FriedewaldDaniel GangerJane N. WinterLeo I. GordonAdam Yuh LinReem KarmaliShuo MaBarbara ProJonathan Moreira

immunologydermatologymedicinehematologynorthwestern universityoncologyimmunosuppressive agentsposttransplant lymphoproliferative disorder

1
2
10 / page

Chetan Vakkalagadda, M.D.

Assistant Professor of Medicine Division of Hematology/Medical Oncology

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Otolaryngology - Head And Neck Surgery

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Center Of Molecular Biology Of Head And Neck Cancer

Molecular Biology of Head and Neck Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Chetan Vakkalagadda, M.d. is currently serving as a Biostatistics Shared Resources Assistant Professor of Medicine Division of Hematology/Medical Oncology at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Chetan Vakkalagadda, M.D.

Oregon Health & Science University

Assistant Professor of Medicine Division of Hematology/Medical Oncology

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated Sclc: A Case Report. JTO Clinical and Research Reports (2026)

recurrent high-grade crsmedicinepharmacologyhematologyclinical researchpathologytranslational medicine

Impact of Incidental Germline Brca1/2 and Palb2 Alterations on Egfr Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer (2025)

Utilizing Tp53 Mutation Status and Initial Disease Burden at Presentation to Risk-Stratify Patients With Advanced Egfr-Mutated Nsclc Treated With Osimertinib.. Journal of Clinical Oncology (2025)

Pp01.124 Impact of Comprehensive vs Limited Ngs on Time to Result and Time to Treatment in Advanced Nsclc. Journal of Thoracic Oncology (2024)

Danielle DresslerChetan V. VakkalagaddaZequn SunJoseph R. FuchsAlex LiuPhilip SilbermanMasha KocherginskyYanis BoumberYoung ChaeAvanthi RagamJyoti PatelNisha Mohindra

surgerymedicinecancer carethoracic oncologyradiation oncologyadvanced nsclcthoracic surgeryoncologybreast cancerclinical researchlung cancer

The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System. Cancers (2024)

Chetan V. VakkalagaddaDanielle B. DresslerZequn SunJoseph FuchsYingzhe LiuPhilip SilbermanAvanthi RagamSheetal KircherJyoti D. PatelNisha A. Mohindra

retrospective analysisnext-generation sequencing workflowsnext-generation sequencingadvanced lung canceracademic health systemlung cancerhealth sciences

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With Ret Fusion-Driven Nsclc and an Acquired Her2 Amplification: Case Report. JTO Clinical and Research Reports (2023)

Chetan VakkalagaddaSabeeha MukitMasha KocherginskySheetal Mehta KircherAparna KalyanMary Frances MulcahyAl Bowen BensonNavdeep ChandelDevalingam Mahalingam

Ep07.04-10 Early-Stage Egfr Mutated Nsclc: Outcomes After Surgical Resection at a Large Academic Medical Center. Journal of Thoracic Oncology (2023)

C. VakkalagaddaD. DresslerJ. FuchsN. KatamM. GurleyN. MohindraY.K. ChaeL. FerrisA. WanA. RagamS. KimA. BharatD. OdellJ. Patel

Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder. Blood (2022)

immunologydermatologymedicinehematologynephrologyextranodal disease involvementtransplantation medicineoncologypost-transplant lymphoproliferative disorder

Posttransplant Lymphoproliferative Disorder (Ptld) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in Ptld. Blood (2022)

immunologydermatologymedicinehematologynorthwestern universityoncologyimmunosuppressive agentsposttransplant lymphoproliferative disorder

1
2
10 / page